Neuphoria Therapeutics Inc (NEUP) 6-K, filed Dec 22, 2021

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OFFOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13a-16 OR15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of December, 2021

Commission File Number: 001-41157

BIONOMICSLIMITED

(Exact Name of Registrant as Specified in Its Charter)

200 Greenhill Road

Eastwood SA 5063

Australia

Tel: +618 81507400

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On December 22, 2021, Bionomics Limited (the “Company”) lodged a press release with the Australian Securities Exchange (ASX), as required by the laws and regulations of Australia, announcing the acquisition of shares by its Executive Chairman. The Announcement is furnished herewith as Exhibit 99.1 to this report on Form 6-K.

On December 22, 2021, the Company lodged a press release with the ASX, as required by the laws and regulations of Australia, announcing the acquisition of shares by one of its directors. The Announcement is furnished herewith as Exhibit 99.2 to this report on Form 6-K.

Exhibits

99.1	Press Release dated December 22, 2021
99.2	Press Release dated December 22, 2021

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Bionomics Limited
Date: December 22, 2021	By:	/s/ Errol De Souza
		Name: Errol De Souza, Ph.D.
		Title: Executive Chairman

EX-99.1

Exhibit 99.1

Appendix 3Y

Change ofDirector’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property andmay be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Bionomics Limited
ABN 53 075 582 740

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Errol De Souza
Date of last notice	1 September 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest<br><br><br>(including registered holder)<br> <br>Note: Provide details of the<br>circumstances giving rise to the relevant interest.
Date of change	22 December 2021
No. of securities held prior to change	366,698 Ordinary Fully Paid Shares<br> <br>500,000<br>Unlisted Options
Class	Unlisted Options
Number acquired	61,216,767 Unlisted Options
Number disposed	0
Value/Consideration<br> <br>Note: If<br>consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	366,698 Fully Paid Ordinary Shares<br> <br>61,716,767<br>Unlisted Options

See chapter 19 for defined terms.

01/01/2011	Appendix 3Y Page 1

Appendix 3Y

Change of Director’s Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

• 47,786,607 Unlisted Options issued pursuant to Dr De Souza’s Employment Agreement dated 20 June 2021, which issue was approved by shareholders pursuant to Resolution 11 of the Company’s Annual General Meeting held on 2 December 2021; and • 13,430,160 Unlisted Options issued following the Company’s initial public offering and listing on the Nasdaq Global Market, which issue was approved by shareholders pursuant to Resolution 12 of the Company’s Annual General Meeting held on 2 December 2021, (being a total of 61,216,767 Unlisted Options).

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder<br> <br>(if issuedsecurities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change<br><br><br>Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration<br> <br>Note: If<br>consideration is non-cash, provide details and an estimated valuation	N/A

See chapter 19 for defined terms.

Appendix 3Y Page 2	01/01/2011

Appendix 3Y

Change of Director’s Interest Notice

Interest after change	N/A

Part 3 – ^+^Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

See chapter 19 for defined terms.

01/01/2011	Appendix 3Y Page 3

EX-99.2

Exhibit 99.2

Appendix 3Y

Change ofDirector’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property andmay be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Bionomics Limited
ABN 53 075 582 740

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Alan David Fisher
Date of last notice	28 November 2016

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest<br><br><br>(including registered holder)<br> <br>Note: Provide details of the<br>circumstances giving rise to the relevant interest.	Thirty Seventh Vilmar Pty Ltd<br> <br>As trustee for A<br>D Fisher Personal Superannuation Fund<br> <br>Mr Alan Fisher is a Director and Secretary, and shareholder of the trustee, and a beneficiary of the<br>trust.
Date of change	20 December 2021
No. of securities held prior to change:<br><br><br>Mr Alan Fisher	500,000 unlisted ESOP Options
Class	Ordinary Fully Paid Shares (Shares)
Number acquired	100,000 Shares
Number disposed	0
Value/Consideration<br> <br>Note: If<br>consideration is non-cash, provide details and estimated valuation	$0.1200 per Share

See chapter 19 for defined terms.

01/01/2011	Appendix 3Y Page 1

Appendix 3Y

Change of Director’s Interest Notice

No. of securities held after change
Mr Alan Fisher	500,000 unlisted ESOP Options
Thirty Seventh Vilmar Pty Ltd as trustee for A D Fisher Personal Superannuation Fund<br><br><br>(Mr Alan Fisher is a Director, Secretary, and shareholder of the trustee, and a beneficiary of the trust)	100,000 Shares
Nature of change<br> <br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in<br>buy-back	On-market trade

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder<br> <br>(if issuedsecurities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change<br><br><br>Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration<br> <br>Note: If<br>consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ^+^Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No

See chapter 19 for defined terms.

Appendix 3Y Page 2	01/01/2011

Appendix 3Y

Change of Director’s Interest Notice

If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

See chapter 19 for defined terms.

01/01/2011	Appendix 3Y Page 3

Neuphoria Therapeutics Inc 6-K, filed Dec 22, 2021

About this 6-K